ReviewFrontiers in medicine2022
Susceptibility-Guided Therapy vs. Bismuth-Containing Quadruple Therapy as the First-Line Treatment for
Review in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- AdjuvantMicrobiology spectrum · 2026Trial
- Susceptibility-Guided Versus Empirical Therapy for Helicobacter pylori Infection in a High Resistance Setting: A Randomised Controlled Trial.MicrobiologyOpen · 2026Trial
- Efficacy and safety of triple therapy with vonoprazan forWorld journal of gastroenterology · 2025Trial
- Trial
- Article
- From Eradication to Holistic Regeneration: Pharmaceutics Strategies for Reshaping Gastric Homeostasis AgainstPharmaceutics · 2026Review
- Navigating the gastric frontier of mucosal immunity againstFrontiers in immunology · 2026Review
- Real-world effectiveness of vonoprazan-based regimen versus rabeprazole-based dual therapy forFrontiers in medicine · 2026Article
- Systematic Evaluation of Helicobacter pylori Susceptibility to Antibiotics Before First-Line Treatment: A Cohort Study.United European gastroenterology journal · 2025Article
- Antibiotic Resistance of Helicobacter pylori: Current Trends in Daegu-Kyungpook.The Korean journal of helicobacter and upper gastrointestinal research · 2025Article
- Review
- Overcoming antibiotic-resistantWorld journal of gastroenterology · 2025Review
- Effectiveness of Susceptibility-Guided Therapy forInfection and drug resistance · 2025Article
- Current and Future Perspectives on the Management ofAntibiotics (Basel, Switzerland) · 2024Review
- Effect of an individualized bismuth quadruple regimen guided by 10-day or 14-day antibiotic susceptibility testing for first-line eradication treatment ofFrontiers in medicine · 2024Article
- Phenotype and genotype analysis forMicrobiology spectrum · 2023Article
- OptimizingGut and liver · 2023Review
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The increased antibiotic resistance of Aim: To evaluate the efficacy, safety, and compliance of susceptibility-guided therapy (SGT) vs. bismuth-containing quadruple therapy (BQT) as the first-line treatment for Materials and Methods: This meta-analysis was performed in accordance with the PRISMA 2009 guidelines. A systematic search in PubMed, Embase, and Cochrane databases was conducted using the combination of " Results: Five studies with 2,110 Conclusion: Compared with BQT, SGT showed a higher efficacy and similar safety as the first-line treatment of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.